Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates

Virology

Volumn 397, Issue 2, 2010, Pages 285-298

  Schaap Nutt, Anne ^a   D'Angelo, Christopher ^a   Scull, Margaret A ^b   Amaro Carambot, Emerito ^a   Nishio, Machiko ^c   Pickles, Raymond J ^b   Collins, Peter L ^a   Murphy, Brian R ^a   Schmidt, Alexander C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Human airway epithelial cultures; Interferon; Non human primates; Parainfluenza virus; V protein

Indexed keywords

BETA INTERFERON; COMPLEMENTARY DNA; LIVE VACCINE; VIRUS PHOSPHOPROTEIN; VIRUS PROTEIN V;

AFRICA; ANIMAL CELL; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOPATHOGENIC EFFECT; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MONKEY; NONHUMAN; PARAINFLUENZA VIRUS; PARAINFLUENZA VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RESPIRATORY EPITHELIUM; SIGNAL TRANSDUCTION; SYNCYTIOTROPHOBLAST; VIROGENESIS; VIRUS REPLICATION;

ANIMALS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; DOWN-REGULATION; GENE KNOCKOUT TECHNIQUES; HUMANS; INTERFERONS; MONKEY DISEASES; PARAINFLUENZA VIRUS 2, HUMAN; RESPIRATORY TRACT INFECTIONS; SIGNAL TRANSDUCTION; VIRAL PROTEINS; VIRUS REPLICATION;

CERCOPITHECUS AETHIOPS; HUMAN PARAINFLUENZA VIRUS 2; PARAINFLUENZA VIRUS; PRIMATES;

EID: 75949087764     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.11.018     Document Type: Article

References (91)

1. Andrejeva J., Young D.F., Goodbourn S., and Randall R.E. Degradation of STAT1 and STAT2 by the V proteins of simian virus 5 and human parainfluenza virus type 2, respectively: consequences for virus replication in the presence of alpha/beta and gamma interferons. J. Virol. 76 5 (2002) 2159-2167
2. Andrejeva J., Childs K.S., Young D.F., Carlos T.S., Stock N., Goodbourn S., and Randall R.E. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc. Natl. Acad. Sci. U.S.A. 101 49 (2004) 17264-17269
3. Bartlett E.J., Cruz A.M., Esker J., Castano A., Schomacker H., Surman S.R., Hennessey M., Boonyaratanakornkit J., Pickles R.J., Collins P.L., Murphy B.R., and Schmidt A.C. Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates. J. Virol. 82 18 (2008) 8965-8977
4. Bartlett E.J., Hennessey M., Skiadopoulos M.H., Schmidt A.C., Collins P.L., Murphy B.R., and Pickles R.J. The role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium. J. Virol. 82 16 (2008) 8059-8070
5. Berghall H., Siren J., Sarkar D., Julkunen I., Fisher P.B., Vainionpaa R., and Matikainen S. The interferon-inducible RNA helicase, mda-5, is involved in measles virus-induced expression of antiviral cytokines. Microbes Infect. 8 8 (2006) 2138-2144
6. Capraro G.A., Johnson J.B., Kock N.D., and Parks G.D. Virus growth and antibody responses following respiratory tract infection of ferrets and mice with WT and P/V mutants of the paramyxovirus Simian Virus 5. Virology 376 2 (2008) 416-428
7. Chew T., Noyce R., Collins S.E., Hancock M.H., and Mossman K.L. Characterization of the interferon regulatory factor 3-mediated antiviral response in a cell line deficient for IFN production. Mol. Immunol. 46 3 (2009) 393-399
8. Childs K., Stock N., Ross C., Andrejeva J., Hilton L., Skinner M., Randall R., and Goodbourn S. mda-5, but not RIG-I, is a common target for paramyxovirus V proteins. Virology 359 1 (2007) 190-200
9. Childs K.S., Andrejeva J., Randall R.E., and Goodbourn S. Mechanism of mda-5 Inhibition by paramyxovirus V proteins. J. Virol. 83 3 (2009) 1465-1473
10. Collins P.L., and Crowe J.E. Respiratory syncytial virus and metapneumovirus. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Strauss S.E. (Eds). Fields Virology. 5th ed. Vol. 2 (2007), Lippincott Williams&Wilkins, Philadelphia 1601-1646 2 vols
11. Curran J., de Melo M., Moyer S., and Kolakofsky D. Characterization of the Sendai virus V protein with an anti-peptide antiserum. Virology 184 1 (1991) 108-116
12. Delenda C., Hausmann S., Garcin D., and Kolakofsky D. Normal cellular replication of Sendai virus without the trans-frame, nonstructural V protein. Virology 228 1 (1997) 55-62
13. Devaux P., Hodge G., McChesney M.B., and Cattaneo R. Attenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys. J. Virol. 82 11 (2008) 5359-5367
14. Didcock L., Young D.F., Goodbourn S., and Randall R.E. Sendai virus and simian virus 5 block activation of interferon-responsive genes: importance for virus pathogenesis. J. Virol. 73 4 (1999) 3125-3133
15. Didcock L., Young D.F., Goodbourn S., and Randall R.E. The V protein of simian virus 5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated degradation. J. Virol. 73 12 (1999) 9928-9933
16. Emeny J.M., and Morgan M.J. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J. Gen. Virol. 43 1 (1979) 247-252
17. Fensterl V., and Sen G.C. Interferons and viral infections. Biofactors 35 1 (2009) 14-20
18. Ferko B., Stasakova J., Romanova J., Kittel C., Sereinig S., Katinger H., and Egorov A. Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J. Virol. 78 23 (2004) 13037-13045
19. Goodbourn S., Didcock L., and Randall R.E. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 81 Pt 10 (2000) 2341-2364
20. Hai R., Martinez-Sobrido L., Fraser K.A., Ayllon J., Garcia-Sastre A., and Palese P. Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J. Virol. 82 21 (2008) 10580-10590
21. Hall S.L., Stokes A., Tierney E.L., London W.T., Belshe R.B., Newman F.C., and Murphy B.R. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res. 22 3 (1992) 173-184
22. He B., Paterson R.G., Stock N., Durbin J.E., Durbin R.K., Goodbourn S., Randall R.E., and Lamb R.A. Recovery of paramyxovirus simian virus 5 with a V protein lacking the conserved cysteine-rich domain: the multifunctional V protein blocks both interferon-beta induction and interferon signaling. Virology 303 1 (2002) 15-32
23. Horvath C.M. Weapons of STAT destruction. Interferon evasion by paramyxovirus V protein. Eur. J. Biochem. 271 (2004) 4621-4628
24. Kapikian A., Bell J., Mastrota F., Huebner R., Wong D., and Chanock R. An outbreak of parainfluenza 2 (croup-associated) virus infection. JAMA 183 (1963) 324-330
25. Karron R.A., and Collins P.L. Chapter 42. Parainfluenza Viruses. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. 5th ed. Vol. 1 (2007), Lippincott Williams & Wilkins, Philadelphia 1497-1526 2 vols
26. Kato A., Kiyotani K., Sakai Y., Yoshida T., and Nagai Y. The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis. EMBO J. 16 3 (1997) 578-587
27. Kato A., Kiyotani K., Sakai Y., Yoshida T., Shioda T., and Nagai Y. Importance of the cysteine-rich carboxyl-terminal half of V protein for Sendai virus pathogenesis. J. Virol. 71 10 (1997) 7266-7272
28. Kato H., Sato S., Yoneyama M., Yamamoto M., Uematsu S., Matsui K., Tsujimura T., Takeda K., Fujita T., Takeuchi O., and Akira S. Cell type-specific involvement of RIG-I in antiviral response. Immunity 23 1 (2005) 19-28
29. Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., Uematsu S., Jung A., Kawai T., Ishii K.J., Yamaguchi O., Otsu K., Tsujimura T., Koh C.S., Reis e Sousa C., Matsuura Y., Fujita T., and Akira S. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441 7089 (2006) 101-105
30. Kawano M., Kaito M., Kozuka Y., Komada H., Noda N., Nanba K., Tsurudome M., Ito M., Nishio M., and Ito Y. Recovery of infectious human parainfluenza type 2 virus from cDNA clones and properties of the defective virus without V-specific cysteine-rich domain. Virology 284 1 (2001) 99-112
31. Kolakofsky D., Pelet T., Garcin D., Hausmann S., Curran J., and Roux L. Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. J. Virol. 72 2 (1998) 891-899
32. Koyama S., Ishii K.J., Kumar H., Tanimoto T., Coban C., Uematsu S., Kawai T., and Akira S. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J. Immunol. 179 7 (2007) 4711-4720
33. Lamb R.A., and Parks G. Paramyxoviridae: the viruses and their replication. 5 ed. In: Fields B., Knipe D., and Howley P. (Eds). "Fields Virology" (2007), Lippincott Williams & Wilkins, Philadelphia 1449-1496
34. Lei Y., Moore C.B., Liesman R.M., O'Connor B.P., Bergstralh D.T., Chen Z.J., Pickles R.J., and Ting J.P. MAVS-mediated apoptosis and its inhibition by viral proteins. PLoS One 4 5 (2009) e5466
35. Leonard V.H., Sinn P.L., Hodge G., Miest T., Devaux P., Oezguen N., Braun W., McCray Jr. P.B., McChesney M.B., and Cattaneo R. Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J. Clin. Invest. 118 7 (2008) 2448-2458
36. Lin G.Y., and Lamb R.A. The paramyxovirus simian virus 5 V protein slows progression of the cell cycle. J. Virol. 74 19 (2000) 9152-9166
37. Lin G.Y., Paterson R.G., and Lamb R.A. The RNA binding region of the paramyxovirus SV5 V and P proteins. Virology 238 2 (1997) 460-469
38. Loo Y.M., Fornek J., Crochet N., Bajwa G., Perwitasari O., Martinez-Sobrido L., Akira S., Gill M.A., Garcia-Sastre A., Katze M.G., and Gale Jr. M. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J. Virol. 82 1 (2008) 335-345
39. Matsui H., Grubb B.R., Tarran R., Randell S.H., Gatzy J.T., Davis C.W., and Boucher R.C. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95 7 (1998) 1005-1015
40. Mosca J.D., and Pitha P.M. Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis. Mol. Cell Biol. 6 6 (1986) 2279-2283
41. Murphy B.R. Current approaches to the development of vaccines effective against parainfluenza viruses. Bull. World Health Organ. 66 3 (1988) 391-397
42. Newman J.T., Surman S.R., Riggs J.M., Hansen C.T., Collins P.L., Murphy B.R., and Skiadopoulos M.H. Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics. Virus Genes 24 1 (2002) 77-92
43. Newman J.T., Riggs J.M., Surman S.R., McAuliffe J.M., Mulaikal T.A., Collins P.L., Murphy B.R., and Skiadopoulos M.H. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses. J. Virol. 78 4 (2004) 2017-2028
44. Nishio M., Tsurudome M., Ito M., Kawano M., Kusagawa S., Komada H., and Ito Y. Isolation of monoclonal antibodies directed against the V protein of human parainfluenza virus type 2 and localization of the V protein in virus-infected cells. Med. Microbiol. Immunol. 188 2 (1999) 79-82
45. Nishio M., Tsurudome M., Ito M., Kawano M., Komada H., and Ito Y. High resistance of human parainfluenza type 2 virus protein-expressing cells to the antiviral and anti-cell proliferative activities of alpha/beta interferons: cysteine-rich V-specific domain is required for high resistance to the interferons. J. Virol. 75 19 (2001) 9165-9176
46. Nishio M., Garcin D., Simonet V., and Kolakofsky D. The carboxyl segment of the mumps virus V protein associates with Stat proteins in vitro via a tryptophan-rich motif. Virology 300 1 (2002) 92-99
47. Nishio M., Tsurudome M., Ito M., Garcin D., Kolakofsky D., and Ito Y. Identification of paramyxovirus V protein residues essential for STAT protein degradation and promotion of virus replication. J. Virol. 79 13 (2005) 8591-8601
48. Nishio M., Tsurudome M., Ito M., and Ito Y. Identification of RNA-binding regions on the P and V proteins of human parainfluenza virus type 2. Medical Microbiological Immunology 195 (2006) 29-36
49. Nishio M., Tsurudome M., Ishihara H., Ito M., and Ito Y. The conserved carboxyl terminus of human parainfluenza virus type 2 V protein plays an important role in virus growth. Virology 362 1 (2007) 85-98
50. Nishio M., Ohtsuka J., Tsurudome M., Nosaka T., and Kolakofsky D. Human parainfluenza virus type 2 V protein inhibits genome replication by binding to the L protein: possible role in promoting viral fitness. J. Virol. 82 13 (2008) 6130-6138
51. Nolan S.M., Surman S.R., Amaro-Carambot E., Collins P.L., Murphy B.R., and Skiadopoulos M.H. Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses. Vaccine 39 23 (2005) 4765-4774
52. Nolan S.M., Skiadopoulos M.H., Bradley K., Kim O.S., Bier S., Amaro-Carambot E., Surman S.R., Davis S., St Claire M., Elkins R., Collins P.L., Murphy B.R., and Schaap-Nutt A. Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3′ genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates. Vaccine 25 34 (2007) 6409-6422
53. Ohgimoto S., Bando H., Kawano M., Okamoto K., Kondo K., Tsurudome M., Nishio M., and Ito Y. Sequence analysis of P gene of human parainfluenza type 2 virus: P and cysteine-rich proteins are translated by two mRNAs that differ by two nontemplated G residues. Virology 177 1 (1990) 116-123
54. Parisien J.P., Lau J.F., Rodriguez J.J., Sullivan B.M., Moscona A., Parks G.D., Lamb R.A., and Horvath C.M. The V protein of human parainfluenza virus 2 antagonizes type I interferon responses by destabilizing signal transducer and activator of transcription 2. Virology 283 2 (2001) 230-239
55. Parisien J.P., Lau J.F., and Horvath C.M. STAT2 acts as a host range determinant for species-specific paramyxovirus interferon antagonism and simian virus 5 replication. J. Virol. 76 13 (2002) 6435-6441
56. Park M.S., Garcia-Sastre A., Cros J.F., Basler C.F., and Palese P. Newcastle disease virus V protein is a determinant of host range restriction. J. Virol. 77 17 (2003) 9522-9532
57. Parrott R., Vargosko A., HW K., Bell J., and Chanock R. Myxoviruses. III. Parainfluenza. Am. J. Public Health 52 (1962) 907-917
58. Paterson R., Leser G., Shaughnessy M., and Lamb R. The paramyxovirus SV5 V protein binds two atoms of zinc and is a structural component of virions. Virology 208 (1995) 121-131
59. Patterson J.B., Thomas D., Lewicki H., Billeter M.A., and Oldstone M.B. V and C proteins of measles virus function as virulence factors in vivo. Virology 267 1 (2000) 80-89
60. Peters K., Chattopadhyay S., and Sen G.C. IRF-3 activation by Sendai virus infection is required for cellular apoptosis and avoidance of persistence. J. Virol. 82 7 (2008) 3500-3508
61. Pickles R.J., McCarty D., Matsui H., Hart P.J., Randell S.H., and Boucher R.C. Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. J. Virol. 72 7 (1998) 6014-6023
62. Poole E., He B., Lamb R.A., Randall R.E., and Goodbourn S. The V proteins of Simian virus 5 and other paramyxoviruses inhibit induction of interferon-beta. Virology 303 1 (2002) 33-46
63. Precious B., Young D.F., Andrejeva L., Goodbourn S., and Randall R.E. In vitro and in vivo specificity of ubiquitination and degradation of STAT1 and STAT2 by the V proteins of the paramyxoviruses simian virus 5 and human parainfluenza virus type 2. J. Gen. Virol. 86 Pt 1 (2005) 151-158
64. Randall R.E., and Bermingham A. NP:P and NP:V interactions of the paramyxovirus simian virus 5 examined using a novel protein:protein capture assay. Virology 224 1 (1996) 121-129
65. Rassa J.C., Wilson G.M., Brewer G.A., and Parks G.D. Spacing constraints on reinitiation of paramyxovirus transcription: the gene end U tract acts as a spacer to separate gene end from gene start sites. Virology 274 2 (2000) 438-449
66. Sims A.C., Baric R.S., Yount B., Burkett S.E., Collins P.L., and Pickles R.J. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J. Virol. 79 24 (2005) 15511-15524
67. Skiadopoulos M.H., Tao T., Surman S.R., Collins P.L., and Murphy B.R. Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts. Vaccine 18 5-6 (1999) 503-510
68. Skiadopoulos M.H., Vogel L., Riggs J.M., Surman S.R., Collins P.L., and Murphy B.R. The genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations. J. Virol. 77 1 (2003) 270-279
69. Stojdl D.F., Lichty B.D., tenOever B.R., Paterson J.M., Power A.T., Knowles S., Marius R., Reynard J., Poliquin L., Atkins H., Brown E.G., Durbin R.K., Durbin J.E., Hiscott J., and Bell J.C. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4 4 (2003) 263-275
70. Sun M., Rothermel T.A., Shuman L., Aligo J.A., Xu S., Lin Y., Lamb R.A., and He B. Conserved cysteine-rich domain of paramyxovirus simian virus 5 V protein plays an important role in blocking apoptosis. J. Virol. 78 10 (2004) 5068-5078
71. Talon J., Salvatore M., O'Neill R.E., Nakaya Y., Zheng H., Muster T., Garcia-Sastre A., and Palese P. Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc. Natl. Acad. Sci. U. S. A. 97 8 (2000) 4309-4314
72. Teng M.N., Whitehead S.S., Bermingham A., St Claire M., Elkins W.R., Murphy B.R., and Collins P.L. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J. Virol. 74 19 (2000) 9317-9321
73. Thompson C.I., Barclay W.S., Zambon M.C., and Pickles R.J. Infection of human airway epithelium by human and avian strains of influenza a virus. J. Virol. 80 16 (2006) 8060-8068
74. Tsurudome M., Nishio M., Komada H., Bando H., and Ito Y. Extensive antigenic diversity among human parainfluenza type 2 virus isolates and immunological relationships among paramyxoviruses revealed by monoclonal antibodies. Virology 171 1 (1989) 38-48
75. Tsurudome M., Nishio M., Ito M., Tanahashi S., Kawano M., Komada H., and Ito Y. Effects of hemagglutinin-neuraminidase protein mutations on cell-cell fusion mediated by human parainfluenza type 2 virus. J. Virol. 82 17 (2008) 8283-8295
76. Ulane C.M., and Horvath C.M. Paramyxoviruses SV5 and HPIV2 assemble STAT protein ubiquitin ligase complexes from cellular components. Virology 304 2 (2002) 160-166
77. Ulane C.M., Kentsis A., Cruz C.D., Parisien J.P., Schneider K.L., and Horvath C.M. Composition and assembly of STAT-targeting ubiquitin ligase complexes: paramyxovirus V protein carboxyl terminus is an oligomerization domain. J. Virol. 79 16 (2005) 10180-10189
78. Van Cleve W., Amaro-Carambot E., Surman S.R., Bekisz J., Collins P.L., Zoon K.C., Murphy B.R., Skiadopoulos M.H., and Bartlett E.J. Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1. Virology 352 1 (2006) 61-73
79. von Messling V., Svitek N., and Cattaneo R. Receptor (SLAM [CD150]) recognition and the V protein sustain swift lymphocyte-based invasion of mucosal tissue and lymphatic organs by a morbillivirus. J. Virol. 80 12 (2006) 6084-6092
80. Wansley E.K., and Parks G.D. Naturally occurring substitutions in the p/v gene convert the noncytopathic paramyxovirus simian virus 5 into a virus that induces alpha/beta interferon synthesis and cell death. J. Virol. 76 20 (2002) 10109-10121
81. Wathelet M.G., Berr P.M., and Huez G.A. Regulation of gene expression by cytokines and virus in human cells lacking the type-I interferon locus. Eur. J. Biochem. 206 3 (1992) 901-910
82. Whitehead S.S., Bukreyev A., Teng M.N., Firestone C.Y., St Claire M., Elkins W.R., Collins P.L., and Murphy B.R. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J. Virol. 73 4 (1999) 3438-3442
83. Wright P.F., Karron R.A., Madhi S.A., Treanor J.J., King J.C., O'Shea A., Ikizler M.R., Zhu Y., Collins P.L., Cutland C., Randolph V.B., Deatly A.M., Hackell J.G., Gruber W.C., and Murphy B.R. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J. Infect. Dis. 193 4 (2006) 573-581
84. Yoneyama M., and Fujita T. Function of RIG-I-like receptors in antiviral innate immunity. J. Biol. Chem. 282 21 (2007) 15315-15318
85. Yoneyama M., Suhara W., Fukuhara Y., Fukuda M., Nishida E., and Fujita T. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J. 17 4 (1998) 1087-1095
86. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., Taira K., Akira S., and Fujita T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5 7 (2004) 730-737
87. Yoneyama M., Kikuchi M., Matsumoto K., Imaizumi T., Miyagishi M., Taira K., Foy E., Loo Y.M., Gale Jr. M., Akira S., Yonehara S., Kato A., and Fujita T. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J. Immunol. 175 5 (2005) 2851-2858
88. Young D.F., Didcock L., Goodbourn S., and Randall R.E. Paramyxoviridae use distinct virus-specific mechanisms to circumvent the interferon response. Virology 269 2 (2000) 383-390
89. Yuasa T., Kawano M., Tabata N., Nishio M., Kusagawa S., Komada H., Matsumura H., Ito Y., and Tsurudome M. A cell fusion-inhibiting monoclonal antibody binds to the presumed stalk domain of the human parainfluenza type 2 virus hemagglutinin-neuraminidase protein. Virology 206 2 (1995) 1117-1125
90. Zhang L., Peeples M.E., Boucher R.C., Collins P.L., and Pickles R.J. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J. Virol. 76 11 (2002) 5654-5666
91. Zhang L., Bukreyev A., Thompson C.I., Watson B., Peeples M.E., Collins P.L., and Pickles R.J. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J. Virol. 79 2 (2005) 1113-1124